Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - May 2017

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of May 2017. This month there are two guidelines that impact upon primary care.

The Type 2 diabetes in adults guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels and identifying and managing long-term complications. It has been updated to include sodium–glucose cotransporter 2 (SGLT-2) inhibitors in the section on drug treatment and the algorithm for blood glucose lowering therapy has been also updated to include these treatment options.

The Eating disorders: recognition and treatment guideline covers the assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa. The guideline includes recommendations on identifying eating disorders.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - May 2017' on Email Share 'NICE Guidance - May 2017' on Delicious Share 'NICE Guidance - May 2017' on Digg Share 'NICE Guidance - May 2017' on Facebook Share 'NICE Guidance - May 2017' on Google+ Share 'NICE Guidance - May 2017' on reddit Share 'NICE Guidance - May 2017' on StumbleUpon Share 'NICE Guidance - May 2017' on Twitter

CKS Updates - April 2017

During April 2017 Clinical Knowledge Summaries were updated for the following topics:

The following topics were all reviewed:

The topics have undergone minor restructures. The most significant change is that the recommendations on primary care management and referral for Dyspepsia, including the management of severe oesophagitis, have been updated in line with the National Institute for Health and Care Excellence (NICE) clinical guideline and the lower age limit has been changed from 16 to 18 years.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - April 2017' on Email Share 'CKS Updates - April 2017' on Delicious Share 'CKS Updates - April 2017' on Digg Share 'CKS Updates - April 2017' on Facebook Share 'CKS Updates - April 2017' on Google+ Share 'CKS Updates - April 2017' on reddit Share 'CKS Updates - April 2017' on StumbleUpon Share 'CKS Updates - April 2017' on Twitter

NICE Guidance - April 2017

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of April 2017. This month there are two guidelines that impact upon primary care.

The Irritable bowel syndrome in adults clinical guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It has been updated in line with more recent guidance on recognition and referral for suspected cancer.

The Alcohol-use disorders clinical guideline covers care for adults and young people with physical health problems that are completely or partly caused by an alcohol-use disorder. It has been updated after an evidence review regarding corticosteroid treatment for people with severe alcohol-related hepatitis.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - April 2017' on Email Share 'NICE Guidance - April 2017' on Delicious Share 'NICE Guidance - April 2017' on Digg Share 'NICE Guidance - April 2017' on Facebook Share 'NICE Guidance - April 2017' on Google+ Share 'NICE Guidance - April 2017' on reddit Share 'NICE Guidance - April 2017' on StumbleUpon Share 'NICE Guidance - April 2017' on Twitter

CKS Updates - March 2017

During March 2017 Clinical Knowledge Summaries were updated for the following topics:

The following topics were all reviewed:

The topics have undergone minor restructures. The most significant change is that all people presenting with suspected TIA within the last week should be referred urgently (to be seen within 24 hours) to a stroke physician without risk stratification.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - March 2017' on Email Share 'CKS Updates - March 2017' on Delicious Share 'CKS Updates - March 2017' on Digg Share 'CKS Updates - March 2017' on Facebook Share 'CKS Updates - March 2017' on Google+ Share 'CKS Updates - March 2017' on reddit Share 'CKS Updates - March 2017' on StumbleUpon Share 'CKS Updates - March 2017' on Twitter

Dabigatran capsule colour change

The manufacturer of dabigatran (Pradaxa®) has written to healthcare professionals to advise that the colour of the capsule is being changed in a move that is likely to improve patient safety.

Dabigatran is available in three strengths, 75mg, 110mg and 150mg. Previously the capsule shell was the same colour for all three strengths with the size and imprint text being different. The new colour will see the 75mg capsule coloured white, the 110mg will be light blue and the 150mg will be two-tone white and light blue. The size and text imprint will remain the same. The changes have also removed sunset yellow as a colouring agent.

Patient support materials are available from company representatives or direct from the company by emailing of calling 01344 742 579.

Action: Clinicians should be aware of this change. Patients who are concerned that their medication has changed in appearance can be reassured and advised to continue to take dabigatran as prescribed.

Share 'Dabigatran capsule colour change' on Email Share 'Dabigatran capsule colour change' on Delicious Share 'Dabigatran capsule colour change' on Digg Share 'Dabigatran capsule colour change' on Facebook Share 'Dabigatran capsule colour change' on Google+ Share 'Dabigatran capsule colour change' on reddit Share 'Dabigatran capsule colour change' on StumbleUpon Share 'Dabigatran capsule colour change' on Twitter

« Older Posts

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,088 spam comments.

atomic-wealth
fond-illness
summer